Rosenblatt Securities Reaffirms Buy Rating for Dolby Laboratories (NYSE:DLB)

Dolby Laboratories (NYSE:DLB)‘s stock had its “buy” rating reaffirmed by analysts at Rosenblatt Securities in a research note issued to investors on Thursday,Benzinga reports. They currently have a $85.00 target price on the electronics maker’s stock. Rosenblatt Securities’ price objective would suggest a potential upside of 37.03% from the stock’s previous close.

Several other research firms have also recently commented on DLB. Barrington Research reduced their target price on shares of Dolby Laboratories from $100.00 to $95.00 and set an “outperform” rating for the company in a research note on Wednesday, November 19th. Wall Street Zen raised Dolby Laboratories from a “hold” rating to a “buy” rating in a report on Monday, January 5th. Finally, Weiss Ratings reiterated a “hold (c-)” rating on shares of Dolby Laboratories in a research report on Monday, December 29th. Three analysts have rated the stock with a Buy rating and two have issued a Hold rating to the stock. According to MarketBeat, Dolby Laboratories currently has an average rating of “Moderate Buy” and a consensus target price of $92.00.

Dolby Laboratories Trading Down 1.1%

Dolby Laboratories stock opened at $62.03 on Thursday. The stock has a 50 day moving average of $65.40 and a two-hundred day moving average of $69.33. Dolby Laboratories has a twelve month low of $61.33 and a twelve month high of $89.66. The stock has a market capitalization of $5.92 billion, a price-to-earnings ratio of 23.59 and a beta of 0.88.

Dolby Laboratories (NYSE:DLB) last released its quarterly earnings results on Tuesday, November 18th. The electronics maker reported $0.99 EPS for the quarter, topping the consensus estimate of $0.70 by $0.29. Dolby Laboratories had a return on equity of 11.99% and a net margin of 18.90%.The business had revenue of $307.02 million during the quarter, compared to analysts’ expectations of $305.76 million. During the same quarter in the prior year, the business earned $0.61 earnings per share. The company’s quarterly revenue was up .7% compared to the same quarter last year. Dolby Laboratories has set its FY 2026 guidance at 4.190-4.340 EPS and its Q1 2026 guidance at 0.790-0.940 EPS. Equities analysts predict that Dolby Laboratories will post 2.94 earnings per share for the current year.

Insider Transactions at Dolby Laboratories

In other news, SVP Shriram Revankar sold 3,000 shares of the firm’s stock in a transaction on Friday, November 21st. The stock was sold at an average price of $65.55, for a total value of $196,650.00. Following the completion of the transaction, the senior vice president owned 67,435 shares in the company, valued at $4,420,364.25. This trade represents a 4.26% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, CEO Kevin J. Yeaman sold 36,699 shares of Dolby Laboratories stock in a transaction on Monday, November 24th. The stock was sold at an average price of $66.91, for a total value of $2,455,530.09. Following the transaction, the chief executive officer directly owned 114,725 shares of the company’s stock, valued at $7,676,249.75. This trade represents a 24.24% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders sold 137,120 shares of company stock valued at $9,184,809. Company insiders own 37.93% of the company’s stock.

Hedge Funds Weigh In On Dolby Laboratories

Several hedge funds have recently added to or reduced their stakes in DLB. Royal Bank of Canada grew its position in shares of Dolby Laboratories by 3.5% in the first quarter. Royal Bank of Canada now owns 68,367 shares of the electronics maker’s stock valued at $5,491,000 after purchasing an additional 2,298 shares during the last quarter. Goldman Sachs Group Inc. lifted its stake in Dolby Laboratories by 218.8% in the 1st quarter. Goldman Sachs Group Inc. now owns 249,574 shares of the electronics maker’s stock valued at $20,043,000 after buying an additional 171,288 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its holdings in Dolby Laboratories by 5.6% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 238,216 shares of the electronics maker’s stock valued at $19,131,000 after buying an additional 12,598 shares during the last quarter. Focus Partners Wealth purchased a new position in Dolby Laboratories during the first quarter worth $390,000. Finally, Wealth Enhancement Advisory Services LLC increased its position in Dolby Laboratories by 43.0% during the second quarter. Wealth Enhancement Advisory Services LLC now owns 17,356 shares of the electronics maker’s stock worth $1,311,000 after buying an additional 5,215 shares in the last quarter. 58.56% of the stock is currently owned by hedge funds and other institutional investors.

Dolby Laboratories Company Profile

Dolby Laboratories, Inc is a global leader in audio and imaging technologies, specializing in the development, licensing and deployment of solutions that enhance entertainment and communications experiences. The company’s core business revolves around creating advanced audio codecs, noise reduction systems and spatial sound technologies for a wide range of applications, including cinema, broadcast, gaming, streaming and personal devices. Dolby’s licensing model enables consumer electronics manufacturers, content creators and service providers to integrate its technologies into products such as televisions, smartphones, home theater systems and set-top boxes.

Among its flagship innovations are Dolby Atmos, an immersive audio format that delivers three-dimensional soundscapes for theaters and home systems; Dolby Digital and Dolby Digital Plus, widely adopted audio compression formats for broadcast and streaming; and Dolby Vision, a high-dynamic-range imaging technology that expands color, contrast and brightness in displays.